111.00p-2.00 (-1.77%)26 Feb 2021, 17:05
Jump to:
Reneuron Group PLC Fundamentals
Company Name | Reneuron Group PLC | Last Updated | 2021-02-26 |
---|---|---|---|
Industry | Biotechnology | Sector | Healthcare |
Shares in Issue | 56.856 m | Market Cap | £63.11 m |
PE Ratio | 0.00 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | -£0.35 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0.0515 | Debt Equity Ratio | 0.0958 |
Asset Equity Ratio | 2.3246 | Cash Equity Ratio | 1.4735 |
Quick Ratio | 1.3016 | Current Ratio | 1.77 |
Price To Book Value | 9.5238 | ROCE | 0 |
Reneuron Group PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Reneuron Group PLC Company Financials
Assets | 2020 | 2019 | 2018 |
---|---|---|---|
Tangible Assets | £1.04 m | £1.34 m | £1.48 m |
Intangible Assets | £186,000.00 | £186,000.00 | £186,000.00 |
Investments | 0 | 0 | 0 |
Total Fixed Assets | £1.23 m | £1.52 m | £1.67 m |
Stocks | 0 | 0 | 0 |
Debtors | £696,000.00 | £834,000.00 | £1.28 m |
Cash & Equivalents | £12.63 m | £26.39 m | £37.41 m |
Other Assets | 0 | 0 | 0 |
Total Assets | £20.38 m | £31.51 m | £43.37 m |
Liabilities | 2020 | 2019 | 2018 |
---|---|---|---|
Creditors within 1 year | £6.45 m | £7.40 m | £5.85 m |
Creditors after 1 year | £707,000.00 | £864,000.00 | £968,000.00 |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | £7.15 m | £8.27 m | £6.82 m |
Net assets | £13.22 m | £23.24 m | £36.55 m |
Equity | 2020 | 2019 | 2018 |
---|---|---|---|
Called up share capital | £318,000.00 | £316,000.00 | £316,000.00 |
Share Premium | £138.18 m | £138.00 m | £138.00 m |
Profit / Loss | -£13.86 m | -£17.23 m | -£20.97 m |
Other Equity | £13.22 m | £23.24 m | £36.55 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | £13.22 m | £23.24 m | £36.55 m |
Ratios | 2020 | 2019 | 2018 |
---|---|---|---|
Debt Ratio | £0.05 | £0.04 | £0.03 |
Debt-to-Equity | £0.05 | £0.04 | £0.03 |
Assets / Equity | 2.3246 | 2.3246 | 2.3246 |
Cash / Equity | 1.4735 | 1.4735 | 1.4735 |
EPS | -£0.35 | -£0.44 | -£0.54 |
Cash Flow | 2020 | 2019 | 2018 |
---|---|---|---|
Cash from operating activities | -£14.30 m | -£11.95 m | -£14.89 m |
Cashflow before financing | -£7.99 m | -£7.58 m | -£362,000.00 |
Increase in Cash | -£7.81 m | -£7.48 m | -£214,000.00 |
Income | 2020 | 2019 | 2018 |
---|---|---|---|
Turnover | £6.07 m | £49,000.00 | £43,000.00 |
Cost of sales | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Operating Profit | -£14.41 m | -£18.30 m | -£20.38 m |
Pre-Tax profit | -£13.86 m | -£17.23 m | -£20.97 m |
Reneuron Group PLC Company Background
Sector | Healthcare |
---|---|
Activities | ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer. |
Latest Interim Date | 24 Nov 2020 |
Latest Fiscal Year End Date | 20 Jul 2020 |
Reneuron Group PLC Directors
Appointed | Name | Position |
---|---|---|
2020-09-10 | Mr. John E. Berriman | Non-Executive Director,Chairman |
2020-08-21 | Mr. Mark James Docherty | Non-Executive Director |
2013-08-15 | Professor Trevor Mervyn Jones CBE | Non-Executive Director |
2020-08-21 | Dr. John David Sinden | Executive Director,Chief Scientific Officer |
2018-07-31 | Dr. Paul Bernard Harper | Non-Executive Director |
2020-08-21 | Mr. Bryan Geoffrey Morton | Non-Executive Director,Chairman |
2021-02-11 | Sir Christopher Thomas Evans OBE | Non-Executive Director |
2020-09-10 | Mr. Simon C Cartmell | Non-Executive Director |
2021-02-11 | Mr. Michael Elliott Hunt | Executive Director,Chief Financial Officer and Company Secretary |
2021-02-11 | Dr. Tim Corn | Non-Executive Director,Chairman |
2021-02-11 | Mr. Olav Hellebo | Executive Director,Chief Executive Officer |
2021-02-11 | Dr. Michael John Owen | Non-Executive Director |
2020-09-10 | Dr. Claudia D'Augusta | Non-Executive Director |
2020-12-15 | Mr. Mark Evans | Non-Executive Director |
Reneuron Group PLC Contact Details
Company Name | ReNeuron Group PLC |
---|---|
Address | Pencoed Business Park, Pencoed, CF35 5HY |
Telephone | +44 2038198400 |
Website | http://www.reneuron.com |
Reneuron Group PLC Advisors
Stockbroker | N+1 Singer |
---|---|
Phone | +44 2074963000 |
Fax | +44 2074963150 |
Nominated Adviser | Stifel Nicolaus Europe Ltd |
---|---|
Phone | +44 2077107600 |
Fax | +44 2077107609 |
Stockbroker | Stifel Nicolaus Europe Ltd |
---|---|
Phone | +44 2077107600 |
Fax | +44 2077107609 |
Financial PR Adviser | Buchanan |
---|---|
Phone | +44 2074665000 |
Fax | +44 2074665001 |
Registrar | Computershare Investor Services PLC |
---|---|
Phone | +44 3707020003 |
Fax | +44 3707036101 |
Solicitor | Covington & Burling LLP |
---|---|
Phone | +44 2070672000 |
Fax | +44 2070672222 |
Stockbroker | Matrix Corporate Capital LLP |
---|---|
Phone | (020) 3206 7000 |
Fax | (020) 3206 7016 |
Bank | Barclays Bank PLC |
---|
Sign up to our
daily email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine

Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Firstgroup PLC | 90.00 | 3.15 |
International Consolidated Airlines Group S.A. | 191.95 | 3.06 |
Pets AT Home Group PLC | 394.40 | 2.98 |
Biffa PLC | 255.00 | 2.41 |
Watches Of Switzerland Group PLC | 638.00 | 2.08 |
Inchcape PLC | 709.00 | 2.01 |
Fallers
Company | Price | % Chg |
---|---|---|
Rightmove PLC | 565.00 | -6.77 |
Edinburgh Worldwide Investment Trust PLC | 350.50 | -6.16 |
Anglo American PLC | 2,772.50 | -6.13 |
Aston Martin Lagonda Global Holdings PLC | 2,008.00 | -6.04 |
British Land Company PLC | 489.60 | -5.77 |
Ferrexpo PLC | 335.20 | -5.47 |